Clinical trials: Metastatic Colorectal Cancer (CRC)
Colorectal Cancer, RAS Mutation
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
- Conditions
- Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
- Trial name
- NCT06206096
- Testing
- oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Early-onset Colorectal Cancer, Late-onset Colorectal Cancer
Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC).
- Trial name
- NCT06040021
- Testing
- standardized treatment
- Volunteers
- 15,244 people
- Sponsor
- Fudan University
Colorectal Cancer
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
This study intends to perform high-intensity focused ultrasound combined with REGOTORI in patients with multiline drug-resistant metastatic colorectal cancer to explore the safety and efficacy of patients.
- Trial name
- NCT04819516
- Testing
- high-intensity focused ultrasound therapy, Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis.
- Trial name
- NCT07512674
- Testing
- Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Colorectal Cancer
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: To determine objective response rate (ORR) To determine time to…
- Trial name
- NCT03517618
- Testing
- S-1+leucovorin
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- TTY Biopharm
Secondary Malignant Neoplasm of Liver, Colorectal Neoplasms
Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study
The purpose of the study is to compare outcomes of laparoscopic versus open liver resection for colorectal metastases in a prospective and randomized study.
- Trial name
- Oslo-CoMet (NCT01516710)
- Testing
- Open liver resection, Laparoscopic liver resection
- Where
- Norway
- Volunteers
- 280 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Carcinoma, Neoplasm Metastasis
CIRSE Registry for LifePearl Microspheres
The application of transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with Irinotecan in liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma will be observed.
- Trial name
- CIREL (NCT03086096)
- Testing
- LifePearl Microspheres loaded with Irinotecan
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Colorectal Cancer
Sacituzumab Govitecan in Metastatic Colorectal Cancer
This is a Phase: II/III, open-label, multicenter (at least four centers in Germany) study of Sacituzumab Govitecan (SG) in metastatic colorectal cancer patients who are refractory to at least two lines of standard of care…
- Trial name
- TROPHIT1 (NCT06243393)
- Testing
- Sacituzumab Govitecan (SG), Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Heidelberg
Metastatic Colorectal Cancer, mCRC
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with…
- Trial name
- NCT05690035
- Testing
- Tislelizumab & Fruquintinib
- Where
- 2 sites in China
- Sponsor
- Sun Yat-sen University
ColoRectal Cancer, Liver Metastasis Colon Cancer
COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.
- Conditions
- ColoRectal Cancer, Liver Metastasis Colon Cancer, Liver Metastases, Surgery
- Trial name
- COLLISION (NCT03088150)
- Testing
- Thermal ablation, Surgical resection
- Where
- Netherlands
- Volunteers
- 618 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer Liver Metastases, Colorectal Cancer
Aspirin in Colorectal Cancer Liver Metastases
The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose acetylsalicylic acid (ASA) can improve disease free survival in patients…
- Conditions
- Colorectal Cancer Liver Metastases, Colorectal Cancer, Liver Metastases
- Trial name
- ASAC (NCT03326791)
- Testing
- Acetylsalicylic acid
- Where
- 14 sites in Denmark, Norway and 1 more
- Volunteers
- 466 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer Metastatic
Colorectal Cancer (CRC) Cetuximab Elderly Frail
OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free…
- Trial name
- NCT01522612
- Testing
- Cetuximab, 5-fluorouracil, leucovorin
- Where
- 3 sites in Belgium, Cyprus and 1 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer Metastatic
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, Phase 3 study
- Trial name
- NCT06008119
- Testing
- Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Metastatic Colorectal Cancer
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous…
- Trial name
- NCT07543744
- Testing
- RPH-030, Vectibix®, Irinotecan
- Where
- 26 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Vitamin D3
XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line…
- Trial name
- NCT03389659
- Testing
- vitamin D3
- Volunteers
- 750 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer
A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, OMP-21M18, when given in combination with FOLFIRI, a standard drug treatment for advanced colorectal cancer.
- Trial name
- NCT01189942
- Testing
- OMP-21M18
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Metastatic Colorectal Cancer, Colorectal Neoplasms
Resection Observatory
Primary Objective: -Evaluate the resection rate (R0/R1) in current practice for aflibercept in combination with irinotecan plus 5-fluorouracil (FOLFIRI) in patients treated for metastatic colorectal cancer (mCRC) after failure of…
- Trial name
- NCT05178745
- Testing
- Fluorouracil, Aflibercept, Irinotecan
- Volunteers
- 140 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients…
- Trial name
- NCT06202001
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences